Familiar fixes for a modern malady: a discussion on the possible cures of COVID-19

Familiar fixes for a modern malady: a discussion on the possible cures of COVID-19

The SARS-CoV-2 virus emerged in December 2019 in Wuhan, China and then spread rapidly all over the world. Scientists are intensifying their research efforts in order to find antivirals specific to the virus and vaccines to treat or prevent COVID-19. Now, for a medicative cure for COVID-19, several d...

Descripció completa

Dades bibliogràfiques
Autor principal:	Amrit Krishna Mitra
Format:	Article
Idioma:	English
Publicat:	AIMS Press 2020-12-01
Col·lecció:	AIMS Molecular Science
Matèries:	covid-19 sars-cov-2 chloroquine hydroxychloroquine lopinavir ritonavir remdesivir favipiravir vitamin c convalescent plasma
Accés en línia:	http://www.aimspress.com/article/10.3934/molsci.2020012?viewType=HTML

Ítems similars

Review of Clinical Trials in COVID-19: Trying to Solve the Clinicians’ Conundrum
per: Amita Athavale, et al.
Publicat: (2020-07-01)

COVID-19: An Update about the Discovery Clinical Trial
per: Jean Jacques Vanden Eynde
Publicat: (2020-05-01)

Therapeutic Strategies in the Management of COVID-19
per: Rajashri R. Naik, et al.
Publicat: (2021-02-01)

A narrative review of antiviral drugs used for COVID-19 pharmacotherapy
per: Subodh Kumar, et al.
Publicat: (2021-01-01)

COVID-19: A Brief Overview of the Discovery Clinical Trial
per: Jean Jacques Vanden Eynde
Publicat: (2020-04-01)

A Comparative Study of Approved Drugs for SARS-CoV-2 by Molecular Docking
per: Achal Mishra, et al.
Publicat: (2021-06-01)

COVID-19 possible medical treatments
per: Marzieh Mohammadi, et al.
Publicat: (2021-01-01)

Current Clinical Trials and Vaccine Development Strategies for Corona Virus Disease (COVID-19)
per: Abhi Bhadra, et al.
Publicat: (2020-05-01)

Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review
per: Shahamah Jomah, et al.
Publicat: (2020-09-01)

Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis
per: Sultan Ayoub Meo, et al.
Publicat: (2020-10-01)

Comparison of effectiveness of various treatment strategies in COVID-19 patients: A Systematic Review
per: Muhammad Shehryar Hussain, et al.
Publicat: (2020-08-01)

Pharmacological management of COVID-19
per: Veena Raghunathan, et al.
Publicat: (2020-01-01)

An early assessment of the efficacy of medicines in the treatment of patients with COVID-19
per: A. S. Kolbin
Publicat: (2020-05-01)

Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19
per: B. K. Romanov
Publicat: (2020-09-01)

Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
per: Xinni Xu, et al.
Publicat: (2020-05-01)

The Rationale for Potential Pharmacotherapy of COVID-19
per: Maha Saber-Ayad, et al.
Publicat: (2020-05-01)

Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review
per: Qomara WF, et al.
Publicat: (2021-11-01)

Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities
per: Milo Gatti, et al.
Publicat: (2021-02-01)

Characteristics and outcomes of acute respiratory distress syndrome related to COVID-19 in Belgian and French intensive care units according to antiviral strategies: the COVADIS multicentre observational study
per: David Grimaldi, et al.
Publicat: (2020-10-01)

COVID-19 treatment in children: A systematic review and meta-analysis
per: Prateek Kumar Panda, et al.
Publicat: (2021-01-01)

Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review
per: Alina Kröker, et al.
Publicat: (2021-11-01)

Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations
per: Stanković Biljana, et al.
Publicat: (2020-01-01)

Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series
per: Hayato Koba, et al.
Publicat: (2020-12-01)

Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications
per: Abubakar AR, et al.
Publicat: (2020-12-01)

Clinical evaluation of selected Pharmacological Treatments used for Coronavirus (COVID-19) pandemic
per: hasan mohammed altemimy
Publicat: (2020-06-01)

Efficacy of lopinavir/ritonavir plus interferon beta compared to hydroxychloroquine in the treatment of COVID-19: A retrospective observational study
per: Motahareh Amirizadeh, et al.
Publicat: (2023-01-01)

High Prevalence of Potential Drug-Drug Interactions Among Patients Treated with Off-label Therapies for COVID-19
per: Allan Ramos-Esquivel, et al.
Publicat: (2022-06-01)

Common anti-COVID-19 drugs and their anticipated interaction with anesthetic agents
per: Shagun B Shah, et al.
Publicat: (2021-01-01)

Progress in the Research and Development of Anti-COVID-19 Drugs
per: Lianzhou Huang, et al.
Publicat: (2020-07-01)

A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial
per: A. Abayomi, et al.
Publicat: (2021-12-01)

Measuring the energy for the molecular graphs of antiviral agents: Hydroxychloroquine, Chloroquine and Remdesivir
per: Muhammad Haroon Aftab, et al.
Publicat: (2024-01-01)

Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial
per: Mehdi Hassaniazad, et al.
Publicat: (2020-10-01)

Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as MPro inhibitors of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
per: Woon Yi Law, et al.
Publicat: (2020-11-01)

The Effectiveness of Hydroxychloroquine Versus Hydroxychloroquine Plus Lopinavir/Ritonavir Therapy in SARSCoV- 2 Pneumonia
per: Ayşe BATIREL, et al.
Publicat: (2021-12-01)

Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study
per: Min Joo Choi, et al.
Publicat: (2021-01-01)

The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial
per: Justin T. Denholm, et al.
Publicat: (2020-07-01)

Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations
per: Paolo Gaibani, et al.
Publicat: (2021-03-01)

Cardiotoxic Drugs Used in the Treatment of COVID-19
per: A. S. Zmitrukevich, et al.
Publicat: (2024-01-01)

Determination of lopinavir/ritonavir concentrations in four different oral solutions for the application of antiretroviral therapy in very young, HIV-1-infected children
per: Nils von Hentig, et al.
Publicat: (2021-05-01)

Scoping insight on antiviral drugs against COVID-19
per: Ahmed S. Ali, et al.
Publicat: (2021-10-01)